-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On January 5, the official website of the State Food and Drug Administration showed that Ruiyang Pharmaceutical's 3 types of generic drugs, Roxatidine Hydrochloride Acetate for Injection, were approved for production and deemed to have been reviewed.
Sexual evaluation
.
According to data from Minet.
com, the sales of this product in China's public medical institutions will be close to 1 billion yuan in 2020, a year-on-year increase of 59.
6%
.
Sexual evaluation
.
According to data from Minet.
com, the sales of this product in China's public medical institutions will be close to 1 billion yuan in 2020, a year-on-year increase of 59.
6%
.
Source: State Food and Drug Administration official website
Roxatidine hydrochloride acetate is a histamine H2 receptor antagonist, which can effectively inhibit gastric acid secretion.
It is clinically used for upper gastrointestinal bleeding (caused by peptic ulcer, acute stress ulcer, hemorrhagic gastritis, etc.
) of low-risk patients
.
It is clinically used for upper gastrointestinal bleeding (caused by peptic ulcer, acute stress ulcer, hemorrhagic gastritis, etc.
) of low-risk patients
.
Including Ruiyang Pharmaceutical, there are currently 3 domestic companies that have production approvals for roxatidine hydrochloride acetate for injection.
According to Minet.
com data, the product will be used in urban public hospitals , county-level public hospitals, urban community centers, and public hospitals in China in 2020.
The terminal sales of township health centers (referred to as Chinese public medical institutions) are close to 1 billion yuan, a year-on-year increase of 59.
6%
.
According to Minet.
com data, the product will be used in urban public hospitals , county-level public hospitals, urban community centers, and public hospitals in China in 2020.
The terminal sales of township health centers (referred to as Chinese public medical institutions) are close to 1 billion yuan, a year-on-year increase of 59.
6%
.
Development of Consistency Evaluation of Roxatidine Hydrochloride Acetate for Injection
Source: Minet Consistency Evaluation Database
At present, 3 companies have submitted the marketing application of rosatidine hydrochloride for injection under the new registration classification.
Among them, the product of Ruiyang Pharmaceutical has been successfully approved, and the first one has passed the consistency evaluation; Sihuan Pharmaceutical has submitted the supplementary application for the consistency of the product , is still under review and approval
.
Among them, the product of Ruiyang Pharmaceutical has been successfully approved, and the first one has passed the consistency evaluation; Sihuan Pharmaceutical has submitted the supplementary application for the consistency of the product , is still under review and approval
.
Ruiyang Pharmaceutical has reviewed injections
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
According to the data from Minet.
com, 19 products of Ruiyang Pharmaceutical have passed or are deemed to have passed the consistency evaluation, including roxatidine hydrochloride acetate for injection, 9 of which are injections
.
com, 19 products of Ruiyang Pharmaceutical have passed or are deemed to have passed the consistency evaluation, including roxatidine hydrochloride acetate for injection, 9 of which are injections
.
Source: Minet database, the official website of the State Food and Drug Administration, etc.
Note: The statistics are as of January 7th, if there are any omissions, please correct me!
On January 5, the official website of the State Food and Drug Administration showed that Ruiyang Pharmaceutical's 3 types of generic drugs, Roxatidine Hydrochloride Acetate for Injection, were approved for production and deemed to have been reviewed.
Sexual evaluation
.
According to data from Minet.
com, the sales of this product in China's public medical institutions will be close to 1 billion yuan in 2020, a year-on-year increase of 59.
6%
.
Sexual evaluation
.
According to data from Minet.
com, the sales of this product in China's public medical institutions will be close to 1 billion yuan in 2020, a year-on-year increase of 59.
6%
.
Source: State Food and Drug Administration official website
Roxatidine hydrochloride acetate is a histamine H2 receptor antagonist, which can effectively inhibit gastric acid secretion.
It is clinically used for upper gastrointestinal bleeding (caused by peptic ulcer, acute stress ulcer, hemorrhagic gastritis, etc.
) of low-risk patients
.
It is clinically used for upper gastrointestinal bleeding (caused by peptic ulcer, acute stress ulcer, hemorrhagic gastritis, etc.
) of low-risk patients
.
Including Ruiyang Pharmaceutical, there are currently 3 domestic companies that have production approvals for roxatidine hydrochloride acetate for injection.
According to Minet.
com data, the product will be used in urban public hospitals , county-level public hospitals, urban community centers, and public hospitals in China in 2020.
The terminal sales of township health centers (referred to as Chinese public medical institutions) are close to 1 billion yuan, a year-on-year increase of 59.
6%
.
According to Minet.
com data, the product will be used in urban public hospitals , county-level public hospitals, urban community centers, and public hospitals in China in 2020.
The terminal sales of township health centers (referred to as Chinese public medical institutions) are close to 1 billion yuan, a year-on-year increase of 59.
6%
.
Development of Consistency Evaluation of Roxatidine Hydrochloride Acetate for Injection
Source: Minet Consistency Evaluation Database
At present, 3 companies have submitted the marketing application of rosatidine hydrochloride for injection under the new registration classification.
Among them, the product of Ruiyang Pharmaceutical has been successfully approved, and the first one has passed the consistency evaluation; Sihuan Pharmaceutical has submitted the supplementary application for the consistency of the product , is still under review and approval
.
Among them, the product of Ruiyang Pharmaceutical has been successfully approved, and the first one has passed the consistency evaluation; Sihuan Pharmaceutical has submitted the supplementary application for the consistency of the product , is still under review and approval
.
Ruiyang Pharmaceutical has reviewed injections
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
According to the data from Minet.
com, 19 products of Ruiyang Pharmaceutical have passed or are deemed to have passed the consistency evaluation, including roxatidine hydrochloride acetate for injection, 9 of which are injections
.
com, 19 products of Ruiyang Pharmaceutical have passed or are deemed to have passed the consistency evaluation, including roxatidine hydrochloride acetate for injection, 9 of which are injections
.
Source: Minet database, the official website of the State Food and Drug Administration, etc.
Note: The statistics are as of January 7th, if there are any omissions, please correct me!
On January 5, the official website of the State Food and Drug Administration showed that Ruiyang Pharmaceutical's 3 types of generic drugs, Roxatidine Hydrochloride Acetate for Injection, were approved for production and deemed to have been reviewed.
Sexual evaluation
.
According to data from Minet.
com, the sales of this product in China's public medical institutions will be close to 1 billion yuan in 2020, a year-on-year increase of 59.
6%
.
Sexual evaluation
.
According to data from Minet.
com, the sales of this product in China's public medical institutions will be close to 1 billion yuan in 2020, a year-on-year increase of 59.
6%
.
Source: State Food and Drug Administration official website
Roxatidine hydrochloride acetate is a histamine H2 receptor antagonist, which can effectively inhibit gastric acid secretion.
It is clinically used for upper gastrointestinal bleeding (caused by peptic ulcer, acute stress ulcer, hemorrhagic gastritis, etc.
) of low-risk patients
.
It is clinically used for upper gastrointestinal bleeding (caused by peptic ulcer, acute stress ulcer, hemorrhagic gastritis, etc.
) of low-risk patients
.
Including Ruiyang Pharmaceutical, there are currently 3 domestic companies that have production approvals for roxatidine hydrochloride acetate for injection.
According to Minet.
com data, the product will be used in urban public hospitals , county-level public hospitals, urban community centers, and public hospitals in China in 2020.
The terminal sales of township health centers (referred to as Chinese public medical institutions) are close to 1 billion yuan, a year-on-year increase of 59.
6%
.
Enterprise Enterprise Enterprise Hospital Hospital HospitalAccording to Minet.
com data, the product will be used in urban public hospitals , county-level public hospitals, urban community centers, and public hospitals in China in 2020.
The terminal sales of township health centers (referred to as Chinese public medical institutions) are close to 1 billion yuan, a year-on-year increase of 59.
6%
.
Development of Consistency Evaluation of Roxatidine Hydrochloride Acetate for Injection
Source: Minet Consistency Evaluation Database
At present, 3 companies have submitted the marketing application of rosatidine hydrochloride for injection under the new registration classification.
Among them, the product of Ruiyang Pharmaceutical has been successfully approved, and the first one has passed the consistency evaluation; Sihuan Pharmaceutical has submitted the supplementary application for the consistency of the product , is still under review and approval
.
Among them, the product of Ruiyang Pharmaceutical has been successfully approved, and the first one has passed the consistency evaluation; Sihuan Pharmaceutical has submitted the supplementary application for the consistency of the product , is still under review and approval
.
Ruiyang Pharmaceutical has reviewed injections
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
According to the data from Minet.
com, 19 products of Ruiyang Pharmaceutical have passed or are deemed to have passed the consistency evaluation, including roxatidine hydrochloride acetate for injection, 9 of which are injections
.
com, 19 products of Ruiyang Pharmaceutical have passed or are deemed to have passed the consistency evaluation, including roxatidine hydrochloride acetate for injection, 9 of which are injections
.
Source: Minet database, the official website of the State Food and Drug Administration, etc.
Source: Minet database, the official website of the State Food and Drug Administration, etc. Note: The statistics are as of January 7th, if there are any omissions, please correct me!
